Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the IGL's second quarter 2023 conference call. At this time, all participants are in the listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at IGL's request. I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for IGL's. Thank you, Operator. Good morning, everyone, and welcome to IGL's second quarter 2023 conference call. You can access slides for today's call by going to the Investors section of our website, agios.com. On today's call, I am joined by our Chief Executive Officer, Brian Goff, Dr. Sarah Hewins, Chief Medical Officer and Head of Research and Development, Sveta Milanova, our Chief Commercial Officer, and Cecilia Jones, Chief Financial Officer. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. And with that, I'll turn the call over to Brian. Thanks, Chris. Good morning, everyone, and thank you for joining us. Augiosis focused on delivering transformative therapies for patients living with rare diseases, and in particular, we're the pioneering leader in PK activation focused on hematologic diseases. In the second quarter, we made significant progress advancing our industry-leading pipeline of PK activators targeting hematologic diseases that share a common underlying pathophysiology. With each step forwa...